Kura Oncology initiated a Phase Ia/Ib trial for ziftomenib in advanced GIST patients post-imatinib failure. The trial aims to determine safety, efficacy, and recommended Phase II dose, with a focus on progression-free survival and overall response rate.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing